...BRCA1 mutation (variant p.S770, c.2309C>G). Mammary-like gland adenocarcinoma of the vulva is a rare but aggressive neop...
...BRCA1 or BRCA2, 34 (41%) met familial risk criteria based on their EHRs; however, an additional 6 (7%) would have met cr...
...BRCA1-associated protein 1 (BAP1) mRNA in LUAD tissues and cells were detected by quantitative real-time PCR (qRT-PCR). ...
...BRCA1/2 mutations, present exploitable vulnerabilities for targeted therapies such as PARP inhibitors (PARPi). This revi...
...BRCA1, BRCA2, and PALB2 strongly associated with BC. FANCM was previously proposed as a possible susceptibility gene for...
...BRCA1/2 mutations (34.1 %) and 27 with GI-positive (61.4 %). In HGSC, HRD-positive status was associated with solid, pse...
...BRCA1/2 (BRCA) mutations plays an important role in the treatment planning of high-risk breast cancer patients, but gene...
...BRCA1 targeted by miR-9, miR-1255b, miR-193b, and miR-148b), non-homologous end joining (with RNF8 being regulated by mi...
BRCA1 mutant cancers are homologous recombination (HR) deficient, and their sensitivity to anti-cancer therapies such as...
...BRCA1/2 pathogenic variant carriers, including cases diagnosed after the implementation of national insurance coverage. ...
联系地址
山东省济南市章丘区文博路2号
齐鲁师范学院 genelibs生信实验室
山东省济南市高新区舜华路750号
大学科技园北区F座4单元2楼
电话： 0531-88819269
版权所有 © 2025.Genelibs 济南弘晖生物技术有限公司 鲁ICP备20007159号-2
